PLUR Stock Overview
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Pluri Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.09 |
| 52 Week High | US$8.56 |
| 52 Week Low | US$3.45 |
| Beta | 1.51 |
| 1 Month Change | -31.81% |
| 3 Month Change | -17.69% |
| 1 Year Change | -36.38% |
| 3 Year Change | -85.92% |
| 5 Year Change | -90.02% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
Pluri gains as PROTO project receives €7.5M EU grant
Sep 06Pluristem Therapeutics renames as Pluri
Jul 25Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?
Dec 04
We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully
Aug 18What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?
Mar 15We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely
Feb 08
Pluristem Therapeutics launches $30M registered direct offering
Feb 02Have Insiders Been Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares?
Jan 04Pluristem expands COVID-19 program in Mexico
Dec 29Pluristem - Moment Of Truth
Dec 08Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)
Nov 30Shareholder Returns
| PLUR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.5% | 1.0% | 1.2% |
| 1Y | -36.4% | 0.7% | 24.9% |
Return vs Industry: PLUR underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: PLUR underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| PLUR volatility | |
|---|---|
| PLUR Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PLUR's share price has been volatile over the past 3 months.
Volatility Over Time: PLUR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 129 | Yaky Yanay | www.pluri-biotech.com |
Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company’s development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications.
Pluri Inc. Fundamentals Summary
| PLUR fundamental statistics | |
|---|---|
| Market cap | US$26.05m |
| Earnings (TTM) | -US$23.95m |
| Revenue (TTM) | US$357.00k |
74.3x
P/S Ratio-1.1x
P/E RatioIs PLUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PLUR income statement (TTM) | |
|---|---|
| Revenue | US$357.00k |
| Cost of Revenue | US$9.00k |
| Gross Profit | US$348.00k |
| Other Expenses | US$24.30m |
| Earnings | -US$23.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.60 |
| Gross Margin | 97.48% |
| Net Profit Margin | -6,708.40% |
| Debt/Equity Ratio | 368.8% |
How did PLUR perform over the long term?
See historical performance and comparison